CoChat

The structure of an MDM2–Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant

Open access
Anil, Burcu, Riedinger, Christiane, Endicott, Jane A., Noble, Martin E. M. · 2013 · Acta Crystallographica Section D Biological Crystallography
Cited by 94

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

The p53-binding site of MDM2 holds great promise as a target for therapeutic intervention in MDM2-amplified p53 wild-type forms of cancer. Despite the extensive validation of this strategy, there are relatively few crystallographically determined co-complex structures for small-molecular inhibitors of the MDM2-p53 interaction available in the PDB. Here, a surface-entropy reduction mutant of the N-terminal domain of MDM2 that has been designed to enhance crystallogenesis is presented. This mutant has been validated by comparative ligand-binding studies using differential scanning fluorimetry and fluorescence polarization anisotropy and by cocrystallization with a peptide derived from p53. Using this mutant, the cocrystal structure of MDM2 with the benchmark inhibitor Nutlin-3a has been determined, revealing subtle differences from the previously described co-complex of MDM2 with Nutlin-2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1107/s0907444913004459

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Overview of the CCP 4 suite and current developments

    Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353 · cited 1×

    “All data were indexed and integrated using the XDS package (Kabsch, 2010) and were further processed using the CCP4 suite (Winn et al., 2011).”
    Method
  • p53, guardian of the genome

    Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · cited 1×

    “Introduction The transcription factor p53 is the major tumour suppressor of the cell and plays a central role in the regulation of many cellular mechanisms such as apoptosis, DNA repair, angiogenesis, survival and senescence (Lane, 1992; Vogelstein et al., 2000; Fridman & Lowe, 2003).”
    Background
  • In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

    Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 20×

    “…intense interest in MDM2 as a target for anticancer drug discovery, only ten small-molecule cocrystal structures have been deposited in the PDB (Vassilev et al., 2004; Ding et al., 2005; Grasberger et al., 2005; Allen et al., 2009; Popowicz et al., 2010; Furet et al., 2012; Graves et al.,…”
    BackgroundMethodInfluential
  • Mdm2 promotes the rapid degradation of p53

    Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×

    “Finally, MDM2, which has E3 ligase activity, targets p53 for proteasomal degradation by ubiquitylation (Haupt et al., 1997; Honda et al., 1997; Wade et al., 2010).”
    Background
  • Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

    Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · cited 5×

    “The crystal structure of MDM2 in complex with p53 (residues 15–29) shows that the interaction is largely mediated by three key residues of p53, namely Phe19, Trp23 and Leu26, and the binding surface on MDM2 is well defined (Kussie et al., 1996).”
    BackgroundMethodInfluential
  • Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

    Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · cited 1×

    “Finally, MDM2, which has E3 ligase activity, targets p53 for proteasomal degradation by ubiquitylation (Haupt et al., 1997; Honda et al., 1997; Wade et al., 2010).”
    Background
  • Amplification of a gene encoding a p53-associated protein in human sarcomas

    Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949

  • Control of apoptosis by p53

    Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401 · cited 1×

    “Introduction The transcription factor p53 is the major tumour suppressor of the cell and plays a central role in the regulation of many cellular mechanisms such as apoptosis, DNA repair, angiogenesis, survival and senescence (Lane, 1992; Vogelstein et al., 2000; Fridman & Lowe, 2003).”
    Background
  • Awakening guardian angels: drugging the p53 pathway

    Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×

    “The p53 gene is altered in 50% of cancers and the function of p53 is down-regulated in cancers where the wild-type protein is retained (Hainaut & Hollstein, 2000; Brown et al., 2009).”
    Background
  • Structure-based design of potent non-peptide MDM2 inhibitors

    Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051147z · Cited by 657 · cited 2×

    “…in MDM2 as a target for anticancer drug discovery, only ten small-molecule cocrystal structures have been deposited in the PDB (Vassilev et al., 2004; Ding et al., 2005; Grasberger et al., 2005; Allen et al., 2009; Popowicz et al., 2010; Furet et al., 2012; Graves et al., 2012; Rew et al., 2012).”
    Background

Show all 13 references

Cited by

See all 94

Metadata

Authors
Anil, B., Riedinger, C., Endicott, J. A., & Noble, M. E. M.
Venue
Acta Crystallographica Section D Biological Crystallography
Published
2013-07-13
Volume
69
Issue
8
Pages
1358-1366
ISSN
  • 0907-4449 (ISSN-L)
  • 1399-0047
OpenAlex
W2003768436
Cited by
94
References
13
FWCI
3.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The structure of an MDM2–Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant. https://app.cochat.ai/papers/10.1107/s0907444913004459
The paper
Anil, B., Riedinger, C., Endicott, J. A., & Noble, M. E. M. (2013). The structure of an MDM2–Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant. Acta Crystallographica Section D Biological Crystallography. https://doi.org/10.1107/s0907444913004459

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.